Werewolf Therapeutics, Inc.
HOWL
$0.86
-$0.06-6.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.82% | -4.25% | -11.71% | -69.96% | -101.24% |
| Total Depreciation and Amortization | -11.45% | -10.57% | -8.19% | -3.91% | 2.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.59% | 22.57% | -9.38% | 14.13% | -7.16% |
| Change in Net Operating Assets | -193.17% | -112.73% | -62.24% | -34.15% | 158.78% |
| Cash from Operations | -21.62% | -6.96% | -23.87% | -210.84% | -72.89% |
| Capital Expenditure | -- | -- | -- | 37.88% | 98.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 37.88% | 98.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -59.29% | -- | -71.93% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 54,666.67% | 103.99% | -- | -71.93% | -114.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.72% | 38.21% | -490.60% | -375.71% | -68.80% |